The aim of the ENKLA-M study is to collect samples from patients with acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), and myelodysplastic syndrome (MDS) to study the evolution of blast phenotype (NK receptor ligands and adhesion molecules) and the biology of patients' NK cells). To do this, blood and bone marrow samples will be collected from patients at diagnosis in order to characterize: (I) the phenotype of ALL and AML blasts with respect to NK receptor ligands and adhesion molecules; (II) the phenotypic profile of NK cells, (III) to further characterize the NK cell repertoire dynamics over time (day 30, day 60, day 90, 6 months, and 1 year), focusing on NK cell populations identified in healthy individuals as particularly effective against leukemia, by defining their phenotypic and transcriptomic profiles; and (IV) the impact of azacitidine (AZA) and donor lymphocyte infusions (DLI) on the biology of NK cells in transplanted patients. Clinical data and KIR/HLA genetic profiles will be used to analyze all NK phenotypic and functional data, with the aim of better defining: (i) the key molecular interactions between NK cells and leukemic cells; (ii) markers of NK cell anti-leukemic efficacy during hematopoietic reconstitution; and (iii) whether AZA/DLI treatment enhances the functional potential of NK cells via KIR-HLA interaction, thereby improving their effectiveness against residual disease.

开始日期2026-02-01

申办/合作机构

Nantes University Hospital

NCT07267013

/ Not yet recruiting临床2期IIT

Clindamycin as an Alternative to Vancomycin in Patients Undergoing Aortic Cardiac Surgery With Extracorporeal Circulation (ECC): a Prospective Single-center Pharmacokinetic Study

Antibiotic prophylaxis is essential for all types of cardiac surgery under Extracorporeal Circulation (ECC), in order to reduce the incidence of surgical site infection (SSI). However, many patients are allergic to beta-lactam antibiotics. All the more, vancomycin antibiotic recommended as replacement is not without adverse effects and frequently administered in an inappropriate manner in terms of pre-intervention timing, linked to its complex use on peripheral venous lines complicated by venotoxicity. Non-compliance with the correct use of antibiotic prophylaxis in surgery is responsible for nosocomial infections, which have an impact on both the patient and the healthcare establishment in terms of costs, particularly in cardiac surgery.
Drug pharmacokinetics are more complex under bypass surgery (high volume of distribution), and studies are needed to determine the correct administration and diffusion of drugs.
In this respect, clindamycin is an antibiotic already used in antibiotic prophylaxis for other surgeries (thoracic, orthopedic...) in cases of allergy to beta-lactam antibiotics, but to date there are no studies examining the pharmacokinetics of this molecule in the context of cardiac surgery under ECC.
The aim of this protocol is to demonstrate the feasibility of using clindamycin in patients undergoing ECC surgery, by verifying that the plasma concentration of clindamycin exceeds the minimum inhibition concentration (MIC) of the main bacteria involved in mediastinitis throughout the surgical procedure.

开始日期2026-01-15

申办/合作机构

Nantes University Hospital

NCT07257289

/ Not yet recruitingN/AIIT

Stratification of Arrhythmic Risk and/or Heart Failure Risk in Patients With Hereditary Heart Disease

Sudden cardiac death (SCD) is one of the leading causes of death in developed countries. These deaths (more than 5,000 per year in France) are due to hereditary arrhythmias or cardiomyopathies. Early diagnosis of SCD is often achieved through family screening, but the main challenge is to stratify the risk of SCD in these patients. Indeed, prevention of SCD relies mainly on the implantation of an automatic defibrillator. The challenge is to identify patients who will develop SCD and avoid implanting an implantable cardioverter defibrillator (ICD) in patients who will never develop arrhythmias but who will face complications related to the ICD (inappropriate shocks, infection, lead failure), leading to a reduced quality of life and significant costs for the healthcare system. However, there is a lack of relevant clinical and biological markers for risk stratification, which rules out any possibility of preventive screening. Most of the clinical and ECG parameters identifying an increased risk of SCD have not been reproduced in replication studies.
In this project, we will develop a data processing and analysis pipeline using artificial intelligence methods to assess the individual risk of serious arrhythmic events or heart failure in patients with hereditary arrhythmic diseases or cardiomyopathies through the automated processing of multimodal data (clinical data, electrocardiogram (ECG), imaging (echocardiography, MRI), genetic data, biomarkers).

开始日期2026-01-01

申办/合作机构

Nantes University Hospital

100 项与 Nantes University Hospital 相关的临床结果

登录后查看更多信息

0 项与 Nantes University Hospital 相关的专利（医药）

登录后查看更多信息

2,050

项与 Nantes University Hospital 相关的文献（医药）

2026-01-01·JPAD-Journal of Prevention of Alzheimers Disease

Brain lymphatic drainage pathways, deep cervical lymphatic surgery, and current insights: A systematic review

Review

作者: Lahmar, Theodore ; Lancien, Ugo ; Boutoleau-Bretonniere, Claire ; Perrot, Pierre ; Thuau, Francois ; Pinard, Gaelle

The discovery of the glymphatic system and the later rediscovery of the meningeal lymphatic network have significantly changed our understanding of central nervous system (CNS) waste clearance. Aging is linked to a gradual decline in these clearance pathways, resulting in waste buildup. As a result, therapeutic strategies targeting cerebral lymphatic function have garnered growing interest, with lymphatic surgery emerging as a promising option. We conducted a review until July 2025, providing an overview of the potential of lymphatic surgical techniques to enhance CNS metabolic waste clearance pathways as a therapeutic approach for brain lymphatic system disorders. Currently available data are limited, nine publications addressing this approach. These studies explore an innovative technique involving lymphatico-venous anastomoses (LVA) targeting deep cervical lymphatic vessels to promote clearance for the treatment of Alzheimer's or Parkinson's diseases. Cerebral lymphatic drainage is critical for effective brain waste elimination such as amyloid-β, phosphorylated tau, and α-synuclein, which are linked to neurodegenerative diseases. Viewing these lymphatic dysfunctions as a form of "cerebral lymphedema," LVA, already used in treating peripheral lymphedema, shows potential as a therapeutic approach. Although clinical evidence is still limited, lymphatic supermicrosurgery presents promising therapeutic possibilities for neurodegenerative diseases and other conditions related to impaired CNS lymphatic outflow.

2025-12-01·Techniques in Coloproctology

Sacral neuromodulation improves functional outcome and quality of life in patients with pouch dysfunction after pan proctocolectomy for ulcerative colitis

Article

作者: Di Giuseppe, M ; Drissi, F ; Ris, F ; Bourreille, A ; Korkmaz, C ; Tréton, X ; Meurette, G

Abstract:

Background:

Postoperative frequency of bowel movements and impaired fecal continence (FI) has a negative impact on quality of life following ileal pouch-anal anastomosis. Sacral neuromodulation (SNM) is a validated treatment of FI, but its effectiveness in patients with ileal pouch-anal anastomosis (IPAA) has been poorly reported. The aim was to assess the results of SNM in patients with IPAA suffering from functional disorders and to compare these results with those of patients routinely treated by SNM for FI.

Methods:

A 3-week test phase was performed before definitive implantation of the pulse generator. Patients’ data were prospectively gathered in a dedicated registry. Patients with IPAA were then compared with a matched-paired control group of patients routinely treated by SNM for FI.

Results:

Between 2007 and 2020, 14 patients with IPAA were tested and 12 (85%) were implanted. This group was compared with a matched group of 20 patients implanted for FI. After a mean follow-up of 4.8 [0.5–16] years, there was a significant decrease of weekly leaks (29 versus 2; p = 0.01), decrease in Wexner score (15 versus 10.8; p = 0.01), and an improvement in quality of life (fecal incontinence quality of life (FIQOL) 1.853 versus 2.42; p = 0.01). Patients with IPAA evolved equally as compared with the control group in terms of Wexner score and quality of life at 6 months, 1 year, and 2 years.

Conclusions:

SNM provides a significant decrease of leaks and improves Wexner scores and quality of life in patients with IPAA. The effectiveness seems comparable to patients routinely treated by SNM for FI. SNM indications could be extended to patients with IPAA who present with bad functional outcome.

2025-12-01·ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE

Edible squash poisoning: cause of hair loss and exanthema

Letter

作者: Robert, M ; Libert, E-P ; Bernier, C ; El Hanache, H

项与 Nantes University Hospital 相关的新闻（医药）

2025-09-09

·ioncology

晚期乳腺癌耐药患者能否插翅而逃

对于激素受体阳性HER2阴性晚期乳腺癌，CDK4/6抑制剂联合内分泌治疗可显著改善患者生存结局。不过，大约50%的患者在CDK4/6抑制剂和内分泌治疗前2年内出现耐药。HER3已被证实对CDK4/6抑制剂和内分泌治疗的耐药发挥关键作用，并且与预后较差显著相关。德帕曲妥单抗由1个大分子HER3单克隆抗体帕曲妥单抗与8个小分子化疗药物德鲁替康缀合而成，已被一期临床研究证实对HER3阳性晚期乳腺癌多线治疗失败患者有效。2021年，法国古斯塔夫鲁西研究院发起二期临床研究，探讨德帕曲妥单抗对激素受体阳性HER2阴性晚期乳腺癌CDK4/6抑制剂、内分泌治疗和化疗耐药患者的有效性和安全性，该研究被命名为ICARUS-BREAST01。伊卡洛斯（ICARUS）是希腊神话人物，传说他与父亲一起用羽毛和蜡制成的翅膀逃离克里特岛。美国天文学会行星科学部官方期刊被命名为《伊卡洛斯》，希腊空军学院的绰号是伊卡洛斯学校，日本金星任务依靠太阳辐射加速的星际风筝也叫伊卡洛斯，美国电影《007：择日而亡》太空武器被命名为伊卡洛斯，美国电影《太阳浩劫》两艘宇宙飞船被称之为伊卡洛斯1号和伊卡洛斯2号，美国游戏《魔兽争霸III》地图DOTA英雄凤凰的名字就是伊卡洛斯，日本漫画《圣斗士星矢》剧场版天界篇有同名天斗士出场，日本电影《哆啦A梦：大雄与翼之勇者》有同名角色，日本动画《名侦探柯南》第218、219、528集都提到伊卡洛斯之翼，日本漫画《航海王》1114话标题即为伊卡洛斯之翼。 ICARUS-BREAST01 (NCT04965766): Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer (ICARUS BREAST) Official Title: Phase 2, Open Label Study of Patritumab Deruxtecan (U3-1402), an Anti-HER3-Antibody Drug Conjugate (ADC), in Patients With Advanced Breast Cancer, With Biomarker Analyses to Characterize Response to Therapy 2025年9月4日，英国《自然》旗下《自然医学》在线发表法国古斯塔夫鲁西研究院、巴黎萨克雷大学、巴黎中央理工学院、保利卡尔梅特研究院、西部癌症研究院、南特大学昂热癌症和免疫学研究中心、蒙彼利埃地区癌症研究院、克劳迪斯雷戈肿瘤研究院、里昂贝拉德中心、安东尼拉卡萨尼中心、巴黎特农医院、居里医院、乔治弗朗索瓦勒克莱尔中心、利摩日大学中心医院、美国第一三共的ICARUS-BREAST01研究报告。该多中心二期临床研究于2021年5月27日至2023年3月9日入组激素受体阳性HER2阴性晚期乳腺癌CDK4/6抑制剂、内分泌治疗和一线化疗耐药患者99例，每3周静脉注射德帕曲妥单抗5.6mg/kg。结果，该研究达到主要终点，客观缓解率达53.5%（90%置信区间：44.8%～62.1%）。最常见的不良事件为疲劳、恶心、腹泻和脱发，发生率分别为83%、75%、53%和40%。治疗前肿瘤样本探索性生物标志物分析表明，客观缓解率与HER3空间分布和雌激素受体基因ESR1突变缺失存在初步关联，无进展生存与HER3表达也存在初步关联，但是有待进一步验证。治疗中肿瘤样本分析表明，治疗效果似乎与肿瘤内德帕曲妥单抗分布和干扰素反应相关。因此，该小样本非对照研究结果表明，对于激素受体阳性HER2阴性晚期乳腺癌CDK4/6抑制剂、内分泌治疗和一线化疗耐药患者，德帕曲妥单抗疗效良好且耐受性可控，故有必要进一步开展大样本随机对照研究与其他药物（包括抗体缀合药物）进行比较。相关链接 HER3阳性晚期乳腺癌德帕首战告捷希腊神话故事：克里特岛国王米诺斯为了关住牛头人身的儿子弥诺陶洛斯，要求建筑师兼发明家代达罗斯建造一座路线设计非常巧妙的迷宫。但是，国王担心迷宫的秘密走漏，于是下令将代达罗斯和他的儿子伊卡洛斯一同关进那座迷宫里的塔楼，以防犯他们逃脱。为了逃出，代达罗斯设计了飞行翼。然而，飞行翼是以蜡结合鸟羽制成，不能耐高热，代达罗斯首先警告伊卡洛斯不要自满或狂妄自大，指示他既不要飞得太低，也不要飞得太高，以免海水打湿他的翅膀或被太阳的热量融化。年轻的伊卡洛斯因初次飞行所带来的喜悦感受，无视父亲的警告，越飞越高，太接近太阳而使蜡翼融化，从天上掉下来，掉进海里而溺死。父亲代达罗斯目睹此景，悲伤地飞回家乡，并将自己身上的那对蜡翼悬挂在奥林帕斯山的阿波罗神殿里，从此不再飞翔。这个神话延伸出了俗谚：不要飞得离太阳太近。 Nat Med. 2025 Sep 4. IF: 50.0 Patritumab deruxtecan in HR+HER2- advanced breast cancer: a phase 2 trial. Pistilli B, Mosele F, Corcos N, Pierotti L, Pradat Y, Le Bescond L, Lacroix-Triki M, Nachabeh G, Alfaro A, Catelain C, Job B, Mami-Chouaib F, Badel S, Farace F, Oulhen M, Kannouche P, Tran DTN, Droin N, Vicier C, Frenel JS, D'Hondt V, Dalenc F, Bachelot T, Ducoulombier A, Benderra MA, Loirat D, Mayeur D, Deluche E, Deneuve J, Cheikh-Hussin R, Guyader P, Signolle N, Godefroy K, Talbot H, Vakalopoulou M, Christodoulidis S, Bernard E, Koudou Y, Sporchia A, Suto F, Li L, Sternberg DW, Michiels S, André F, Sellami D, Montagnac G. Gustave Roussy, Villejuif, France; Gustave Roussy, Université Paris-Saclay, Villejuif, France; Université Paris-Saclay, Gustave Roussy, Villejuif, France; Gustave Roussy, Paris, France; CentraleSupélec, Université Paris-Saclay, Gif-Sur-Yvette, France; Institut Paoli Calmettes, Marseille, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Nantes Université, Centre de Recherche en Cancérologie et Immunologie Nantes Angers, Nantes, France; Institut Régional du Cancer de Montpellier, Montpellier, France; Oncopole Claudius Regaud, Toulouse, France; Centre Léon Bérard, Lyon, France; Centre Antoine Lacassagne, Nice, France; Tenon Hospital, Paris, France; Curie Hospital, Paris, France; Centre Georges Francois Leclerc, Dijon, France; Centre Hopital-Universitaire, Limoges, France; Daiichi Sankyo Inc., Basking Ridge, NJ, USA. Antibody-drug conjugates have shown impressive clinical outcomes, particularly in metastatic breast cancer, but biomarkers to predict response and resistance remain unidentified. Here we report the results of ICARUS-BREAST01, a phase 2 study evaluating efficacy, safety and biomarkers of response and resistance to patritumab deruxtecan (HER3-DXd), in patients with HR+HER2- metastatic breast cancer, who previously progressed on CDK4/6 inhibitors and one line of chemotherapy. From May 2021 to June 2023, 99 patients were enrolled to receive HER3-DXd 5.6 mg kg-1 intravenously every 3 weeks. The study met its primary endpoint, showing an overall response rate of 53.5% (90% confidence interval [44.8-62.1%]). The most frequent adverse events were fatigue (83%), nausea (75%), diarrhea (53%) and alopecia (40%). Exploratory biomarker analysis of baseline tumor samples suggested preliminary associations between overall response rate and both HER3 spatial distribution and absence of estrogen receptor 1 (ESR1) mutations, as well as between progression-free survival and HER3 expression, pending further validation. Analysis of on-treatment tumor samples showed that treatment efficacy seems to be associated with antibody-drug conjugate intratumoral distribution and interferon response. Overall, HER3-DXd showed promising activity and manageable tolerability in patients with HR+HER2- metastatic breast cancer who progressed on CDK4/6 inhibitors. These findings highlight the need for larger trials to define HER3-DXd efficacy relative to other drugs, including antibody-drug conjugates. ClinicalTrials.gov Identifier: NCT04965766 PMID: 40908353 DOI: 10.1038/s41591-025-03885-3 （来源：SIBCS）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

临床2期临床1期抗体药物偶联物

2024-11-22

·PipelineReview

First Patient Treated in Phase I/II Trial in Acute Myeloid and Acute Lymphoblastic Leukemia with Lu177-PentixaTher, Expanding the Evidence Base for Targeted Radiotherapy Approach

BERLIN and WURZBURG, Germany I November 21, 2024 I Pentixapharm Holding AG, a biopharmaceutical company developing innovative first-in-class radiopharmaceuticals, today announced that the first patient has been treated in a Phase I/II clinical trial evaluating the safety and efficacy of Lu177-PentixaTher, a novel radiopharmaceutical therapy, in adults for relapsed/refractory CXCR4 positive acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). The trial, funded by the French Ministry of Health and led by a renowned investigator team from the University Hospital in Nantes, represents a significant step toward expanding targeted radiotherapy options for hematologic malignancies. The investor-initiated study, named PENTILULA (ClinicalTrials.gov ID: NCT06356922) is a multicenter, open-label trial in which up to 21 patients with relapsed/refractory AML or ALL will be enrolled over a period of 24 months, with a total study duration of 36 months. The primary objective is to determine the maximal tolerated dose (MTD) of Lu177-PentixaTher, and to examine key efficacy parameters such as overall response rate (ORR) and complete remission (CR) after infusion of the novel radiotherapeutic agent. Following a peer-reviewed publication in January 2023 in the prestigious Journal of Nuclear Medicine highlighting promising clinical results in the treatment of patients suffering from T-cell lymphoma, further evidence continues to be built up about the potential of Pentixapharm’s lead candidate, PentixaTher, for the treatment of haemato-oncological diseases. The study is significant for Pentixapharm insofar as the incidence of ALL and AML, and hence the medical need, is much higher than that for T-Cell lymphoma. The PENTILULA trial is the first trial that combines PentixaTher with Lutetium-177, a radioisotope widely and successfully used for the treatment of castration resistant prostate cancer or neuroendocrine tumors. Acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) are aggressive and life-threatening blood cancers that affect thousands of people worldwide each year. AML is the most common type of acute leukemia in adults, with an incidence of approximately 20,000 new cases per year and low five-year survival rate of 31.9% in the United States [1]. ALL is the most common type of cancer in children, with a high incidence in adults as well. Current treatment options often involve intensive chemotherapy and stem cell transplantation, which can have severe side effects. Effective radiotherapies in other indications are currently reimbursed with more than 100,000 USD per patient. “Although treatments for acute leukemia have advanced, many patients continue to have limited options and face poor outcomes. We believe PentixaTher holds significant potential to address these unmet needs, offering a valuable radiopharmaceutical theranostic approach tailored to the individual patients with hematologic malignancies,” explains Dr. Dirk Pleimes, Group CEO and CMO at Pentixapharm. “We are delighted that leading experts such as Professor Françoise Kraeber-Bodéré of the Nuclear Medicine Department and Professor Patrice Chevallier of the Hematology Department in Nantes have decided to initiate this study to evaluate this novel radiotherapeutic treatment option. We are committed to providing our full support, leveraging our therapeutic knowledge with PentixaTher and facilitating access to the compound to drive this important research forward.” Professor Françoise Kraeber-Bodéré is the Head of the department of Nuclear Medicine at the University Hospital in Nantes, France, and an expert of the Oncology committee of the French Society of Nuclear Medicine (SFMN) as well as of the Oncology and Therapy committee of the European Association of Nuclear Medicine. She is on the scientific board of the French Lymphoma research group LYSA and expert for PET imaging in lymphoma and myeloma. Professor Patrice Chevallier is a specialist in Hematology and member of the executive committee and scientific council of HéMA, an umbrella organization for hemato-oncological research in Western France. About Pentixapharm Pentixapharm is a clinical-stage biotech company discovering and developing novel targeted radiopharmaceuticals with its offices in Berlin and Würzburg, Germany. It is committed to developing CXCR4 ligand-based first-in-class radiopharmaceutical approaches with a clear commercial pathway for diagnostic and therapeutic programs in a number of hematological and solid cancers, as well as cardiovascular, endocrine and inflammatory diseases. Its Pipeline includes PentixaTher, an Yttrium-90 or Lutetium-177 based therapeutic against non-Hodgkin lymphomas (NHL), and PentixaFor, a Gallium-68 based companion diagnostic for blood cancers and cardiovascular diseases. PentixaTher is an innovative radiotherapeutic that specifically targets the chemokine-4 receptor (CXCR4). Background material about its potential for the treatment of haematooncological diseases can be found at: About Nantes University Hospital Nantes University Hospital (CHU de Nantes) is one of France’s leading healthcare institutions, recognized for its excellence in various medical specialties including cardiology, transplants, oncology, and neuroscience. The hospital is also a key player in medical research and innovation, conducting thousands of clinical trials and contributing to significant advancements in healthcare. [1] https://seer.cancer.gov/statfacts/html/amyl.html SOURCE: Pentixapharm

临床研究

2024-11-21

·GlobeNewswire-Health Care

First Patient Treated in Phase I/II Trial in Acute Myeloid and Acute Lymphoblastic Leukemia with Lu177-PentixaTher, Expanding the Evidence Base for Targeted Radiotherapy Approach

BERLIN and WURZBURG, Germany, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Pentixapharm Holding AG, a biopharmaceutical company developing innovative first-in-class radiopharmaceuticals, today announced that the first patient has been treated in a Phase I/II clinical trial evaluating the safety and efficacy of Lu177-PentixaTher, a novel radiopharmaceutical therapy, in adults for relapsed/refractory CXCR4 positive acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). The trial, funded by the French Ministry of Health and led by a renowned investigator team from the University Hospital in Nantes, represents a significant step toward expanding targeted radiotherapy options for hematologic malignancies. The investor-initiated study, named PENTILULA (ClinicalTrials.gov ID: NCT06356922) is a multicenter, open-label trial in which up to 21 patients with relapsed/refractory AML or ALL will be enrolled over a period of 24 months, with a total study duration of 36 months. The primary objective is to determine the maximal tolerated dose (MTD) of Lu177-PentixaTher, and to examine key efficacy parameters such as overall response rate (ORR) and complete remission (CR) after infusion of the novel radiotherapeutic agent. Following a peer-reviewed publication in January 2023 in the prestigious Journal of Nuclear Medicine highlighting promising clinical results in the treatment of patients suffering from T-cell lymphoma, further evidence continues to be built up about the potential of Pentixapharm’s lead candidate, PentixaTher, for the treatment of haemato-oncological diseases. The study is significant for Pentixapharm insofar as the incidence of ALL and AML, and hence the medical need, is much higher than that for T-Cell lymphoma. The PENTILULA trial is the first trial that combines PentixaTher with Lutetium-177, a radioisotope widely and successfully used for the treatment of castration resistant prostate cancer or neuroendocrine tumors. Acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) are aggressive and life-threatening blood cancers that affect thousands of people worldwide each year. AML is the most common type of acute leukemia in adults, with an incidence of approximately 20,000 new cases per year and low five-year survival rate of 31.9% in the United States [1]. ALL is the most common type of cancer in children, with a high incidence in adults as well. Current treatment options often involve intensive chemotherapy and stem cell transplantation, which can have severe side effects. Effective radiotherapies in other indications are currently reimbursed with more than 100,000 USD per patient. “Although treatments for acute leukemia have advanced, many patients continue to have limited options and face poor outcomes. We believe PentixaTher holds significant potential to address these unmet needs, offering a valuable radiopharmaceutical theranostic approach tailored to the individual patients with hematologic malignancies,” explains Dr. Dirk Pleimes, Group CEO and CMO at Pentixapharm. “We are delighted that leading experts such as Professor Françoise Kraeber-Bodéré of the Nuclear Medicine Department and Professor Patrice Chevallier of the Hematology Department in Nantes have decided to initiate this study to evaluate this novel radiotherapeutic treatment option. We are committed to providing our full support, leveraging our therapeutic knowledge with PentixaTher and facilitating access to the compound to drive this important research forward.” Professor Françoise Kraeber-Bodéré is the Head of the department of Nuclear Medicine at the University Hospital in Nantes, France, and an expert of the Oncology committee of the French Society of Nuclear Medicine (SFMN) as well as of the Oncology and Therapy committee of the European Association of Nuclear Medicine. She is on the scientific board of the French Lymphoma research group LYSA and expert for PET imaging in lymphoma and myeloma. Professor Patrice Chevallier is a specialist in Hematology and member of the executive committee and scientific council of HéMA, an umbrella organization for hemato-oncological research in Western France. About Pentixapharm Pentixapharm is a clinical-stage biotech company discovering and developing novel targeted radiopharmaceuticals with its offices in Berlin and Würzburg, Germany. It is committed to developing CXCR4 ligand-based first-in-class radiopharmaceutical approaches with a clear commercial pathway for diagnostic and therapeutic programs in a number of hematological and solid cancers, as well as cardiovascular, endocrine and inflammatory diseases. Its Pipeline includes PentixaTher, an Yttrium-90 or Lutetium-177 based therapeutic against non-Hodgkin lymphomas (NHL), and PentixaFor, a Gallium-68 based companion diagnostic for blood cancers and cardiovascular diseases. PentixaTher is an innovative radiotherapeutic that specifically targets the chemokine-4 receptor (CXCR4). Background material about its potential for the treatment of haematooncological diseases can be found at: https://edoc.mdc-berlin.de/id/eprint/24012/1/24012oa.pdf About Nantes University Hospital Nantes University Hospital (CHU de Nantes) is one of France's leading healthcare institutions, recognized for its excellence in various medical specialties including cardiology, transplants, oncology, and neuroscience. The hospital is also a key player in medical research and innovation, conducting thousands of clinical trials and contributing to significant advancements in healthcare. For more information, please contact: Pentixapharm Holding AGPhillip Eckert, Investor Relationsir@pentixapharm.comTel. +49 30 94893232www.pentixapharm.com [1] https://seer.cancer.gov/statfacts/html/amyl.html

临床研究

100 项与 Nantes University Hospital 相关的药物交易

登录后查看更多信息

100 项与 Nantes University Hospital 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2025年12月13日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床前

临床1期

临床2期

临床3期

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

MIBI-Tc99m/Iodine-123	结节性甲状腺肿更多	临床3期
177Lu-Pentixather ( CXCR4 )	急性白血病更多	临床1/2期
Eight Treg ( CD8 )	肾移植排斥反应更多	临床1期
CLEC-1 antagonist(OSE Immunotherapeutics) ( CLEC-1 )	肿瘤更多	临床前
Epratuzumab Y-90 ( CD22 )	急性淋巴细胞白血病更多	终止